Expression and purification of prostate-specific membrane antigen in the baculovirus expression system and recognition by prostate-specific membrane antigen-specific T cells

Journal of Immunotherapy

Volumn 22, Issue 4, 1999, Pages 346-355

  Lodge, Patricia A ^a,d   Childs, Ronnie A ^a,d   Monahan, Steven J ^a,d   McLean, Joanne G ^a,d   Sehgal, Anil ^b,d   Boynton, Alton L ^a,c,d   Salgaller, Michael L ^a,d   Murphy, Gerald P ^a,c,d  

^a Northwest Biotherapeutics Inc   (United States)

^b Deke Slayton Ctr Brain Cancer S   (United States)

^c PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^d NORTHWEST HOSPITAL   (United States)

Author keywords

Glycoprotein antigens; Immunotherapy; Prostate cancer; Prostate specific membrane antigen; T cell recognition

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RECOMBINANT PROTEIN; VIRUS VECTOR;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PURIFICATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BACULOVIRUS; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE EXPRESSION SYSTEM; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INSECT; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION; TUMOR CELL LINE;

EID: 0033039938     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-199907000-00008     Document Type: Article

References (25)

1. Wingo PA, Landis S. Ries LAG. An adjustment to the 1997 estimate for new prostate cancer cases. CA Cancer J Clin 1997;47:239-42.
2. Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer 1990;66:1039-44.
3. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization-implications for immunotherapy of prostate cancer. J Immunol 1997;159:3113-17.
4. Liu KJ, Chatta GS, Twardzik DR, Vedvick TS, True LD, Spies AG, Cheever MA. Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis-implications for prostate cancer therapy. J Immunol 1997;159:472-80.
5. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-11.
6. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93:749-53.
7. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-5.
8. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-36.
9. Murphy GP, Tino WT, Holmes EH, et al. Measurement of prostate-specific membrane antigen in the serum with a new antibody. Prostate 1996;28:266-71.
10. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 1996;28:65-9.
11. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous den dritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-80.
12. Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Muiphy GP. Dendritic cell-based immunotherapy of prostate cancer. Crit Rev Immunol 1998;18:109-19.
13. Kidd IM, Emery VC. The use of baculoviruses as expression vectors. Appl Biochem Biotechnol 1993;42:137-59.
14. Holmes EH, Greene TG, Tino WT, Boynton AL, Aldape HC, Misrock SL, Murphy GP. Analysis of glycosylation of prostatespecific membrane antigen derived from LNCaP cells, prostatic carcinoma tumors, and serum from prostate cancer patients. Prostate 1996;7:25-9.
15. Israeli RS, Powell CT, Fair WR, Heston WDW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cane Res 1993;53:227-30.
16. Miller LK. Baculoviruses as gene expression vectors. Ann Rev Microbiol 1988;42:177-99.
17. Mackow ER, Vo PT, Broome R, Bass D, Greenberg HB. Immunization with baculovirus-expressed vp4 protein passively protects against simian and murine rotavirus challenge. J Virol 1990;64:1698-1703.
18. McCown J, Cochran M, Putnak R, Feighny R, Burrous J, Henchal E, Hoke C. Protection of mice against lethal Japanese encephalitis with a recombinant baculovirus vaccine. Am J Trop Med Hyg 1990;42:491-9.
19. Sallusto F, Celia M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995;182:389-400.
20. Prasad SV, Mujtaba S, Lee VH, Dunbar BS. Immunogenicity enhancement of recombinant rabbit 55-kilodalton zona pellucida protein expressed using the baculovirus expression system. Biol Reprod 1995;52:1167-78.
21. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med 1994;180:745-9.
22. Doe B, Steimer KS, Walker CM, 2. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Eur J Immunol 1994;24:2369-76.
23. Botarelli P, Houlden BA, Haigwood NL, Servis C, Montagna D, Abrignani S. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. J Immunol 1991;147:3128-32.
24. Skipper JCA, Hendrickson RC, Gulden PH, et al. An HLA-A2restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 1996;183:527-34.
25. Johansson BE, Price PM, Kilboume ED. Immunogenicity of influenza A virus N2 neuraminidase produced in insect larvae by baculovirus recombinants. Vaccine 1995;13:841-5.